{
  "context": {
    "rules": [
      "Rule1: The researcher secures a patent for the drug or the researcher forms a collaboration with the institution.",
      "Rule2: If the researcher forms a collaboration with the institution, then, provided that the researcher gains peer recognition in the field, the drug cures the patient of the disease.",
      "Rule3: If the researcher encounters a regulatory hurdle with the agency, then the researcher delays approval of the drug.",
      "Rule4: The researcher encounters a regulatory hurdle with the agency or, if the researcher secures a patent for the drug, then, given that the researcher gains peer recognition in the field, the drug cures the patient of the disease.",
      "Rule5: If the researcher appeals the decision of the agency, then the researcher does not delay approval of the drug.",
      "Rule6: If the researcher abandons the project on the drug, then the researcher loses funding from the grant.",
      "Rule7: If the researcher abandons the project on the drug, then the researcher does not lose funding from the grant.",
      "Rule8: The researcher changes the methodology of the protocol or the drug cures the patient of the disease.",
      "Rule9: If the researcher identifies a side effect of the drug, then the researcher consults the ethics board of the committee.",
      "Rule10: If the researcher modifies the formulation of the drug, then the researcher does not change the methodology of the protocol.",
      "Rule11: If the researcher reviews literature in the database, then the researcher identifies a side effect of the drug or the researcher modifies the formulation of the drug.",
      "Rule12: If the researcher conducts a meta-analysis of the studies, then the researcher identifies a side effect of the drug or the researcher modifies the formulation of the drug.",
      "Rule13: If the researcher submits an application to the regulatory body, then the researcher reviews literature in the database or the researcher conducts a meta-analysis of the studies.",
      "Rule14: If the researcher exceeds benchmarks with the drug, then the researcher achieves a milestone in the timeline.",
      "Rule15: The researcher exceeds benchmarks with the drug or the researcher meets endpoints in the trial.",
      "Rule16: If the researcher meets endpoints in the trial, then the researcher proceeds to clinical trial with the drug.",
      "Rule17: The researcher faces public criticism in the media or, if the researcher presents findings at the conference, then the drug cures the patient of the disease.",
      "Rule18: If the researcher issues a clarification in the statement, then the researcher does not face public criticism in the media.",
      "Rule19: If the researcher passes the in vitro test with the drug, then the researcher does not halt the trial of the drug.",
      "Rule20: If the researcher proceeds to clinical trial with the drug, then, under the condition that the researcher tests the drug in vitro, the researcher passes the in vitro test with the drug.",
      "Rule21: If the researcher receives funding from the grant, then the researcher proceeds to clinical trial with the drug.",
      "Rule22: The researcher receives funding from the grant or the researcher receives support from the pharmaceutical company.",
      "Rule23: If the researcher receives support from the pharmaceutical company, then the researcher proceeds to clinical trial with the drug.",
      "Rule24: If the researcher publishes a paper in the journal, then the drug cures the patient of the disease.",
      "Rule25: The researcher publishes a paper in the journal or the researcher presents findings at the conference.",
      "Rule26: If the researcher presents findings at the conference, then the researcher gains peer recognition in the field.",
      "Rule27: If it is not the case that the researcher synthesizing the drug leads to the drug curing the patient of the disease, then the researcher halts the trial of the drug.",
      "Rule28: If the drug does not cure the patient of the disease, then the researcher abandons the project on the drug."
    ],
    "facts": [
      "Fact1: The researcher synthesizes the drug.",
      "Fact2: The researcher appeals the decision of the agency.",
      "Fact3: The researcher submits an application to the regulatory body.",
      "Fact4: The researcher issues a clarification in the statement.",
      "Fact5: The researcher tests the drug in vitro.",
      "Fact6: The researcher does not consult the ethics board of the committee.",
      "Fact7: The researcher does not achieve a milestone in the timeline."
    ]
  },
  "question": "The drug cures the patient of the disease."
}